Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease (COPD)
Scientific study published in Thorax (doi: 10.1136/thoraxjnl-2017-210067)
Background
Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers with chronic obstructive pulmonary disease (COPD). We sought to investigate whether the two drugs are associated with serious adverse cardiovascular and neuropsychiatric events in smokers with COPD.
Methods
In a retrospective cohort study, we used data from 14,350 COPD patients included in the QResearch® database, which holds data from 753 National Health Service general practices across England. We identified COPD patients who received a prescription of nicotine replacement therapy (NRT; N=10,426; reference group), bupropion (N=350), or varenicline (N=3,574) in the period between January 2007 and June 2012. Patients were followed-up for six months to compare incident cardiovascular (i.e., ischaemic heart disease, stroke, heart failure, peripheral vascular disease, and cardiac arrhythmias) and neuropsychiatric (i.e., depression and self-harm) events using Cox proportional hazards models, adjusted for potential confounders. Propensity score analysis was used as an additional approach to account for potential confounding by indication. We also modelled the effects of possible unmeasured confounders.
Findings
Neither bupropion nor varenicline showed an increased risk of adverse events compared with NRT. Varenicline was associated with a significantly reduced risk of heart failure (HR=0.56, 95%CI=0.34-0.92) and depression (HR=0.73, 95%CI=0.613-0.86). Similar results were obtained from the propensity score analysis. Modelling of unmeasured confounding provided additional evidence that an increased risk of these adverse events was very unlikely.
Interpretation
In smokers with COPD, varenicline and bupropion do not appear to be associated with an increased risk of cardiovascular events, depression or self-harm when compared with NRT.
About this entry
You’re currently reading “Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease (COPD),” an entry on Prof. Dr. Daniel Kotz
- Published:
- May 9, 2017 / 16:47
- Category:
- Publications
- Tags:
No comments yet
Jump to comment form | comment rss [?] | trackback uri [?]